Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Paoletti

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Future Oncology (London, England)|August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancerRayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
Gynecologic Oncology|June 26, 2026
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG networkThomas Montassier, Enora Laas, Judicael Hotton, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMARTBirgit Geoerger, Francisco Bautista, Nicolas André, et al.
JAMA Network Open|January 11, 2020
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysisXavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, et al.
JNCI Cancer Spectrum|February 19, 2021
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer PatientsClémence Basse, Sarah Diakite, Vincent Servois, et al.
BMJ Open|June 17, 2026
HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trialNicholas Heming, Elodie Baron, Grégoire Muller, et al.
Journal of the National Cancer Institute|October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysisXavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
Nature Medicine|October 19, 2023
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trialBirgit Geoerger, Xavier Paoletti, Francisco Bautista, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Future Oncology (London, England)|August 19, 2024
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancerRayan Kabirian, Olivier Tredan, Frederik Marmé, et al.
Gynecologic Oncology|June 26, 2026
Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG networkThomas Montassier, Enora Laas, Judicael Hotton, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMARTBirgit Geoerger, Francisco Bautista, Nicolas André, et al.
JAMA Network Open|January 11, 2020
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysisXavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, et al.
JNCI Cancer Spectrum|February 19, 2021
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer PatientsClémence Basse, Sarah Diakite, Vincent Servois, et al.
BMJ Open|June 17, 2026
HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trialNicholas Heming, Elodie Baron, Grégoire Muller, et al.
Journal of the National Cancer Institute|October 11, 2013
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysisXavier Paoletti, Koji Oba, Yung-Jue Bang, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
Nature Medicine|October 19, 2023
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trialBirgit Geoerger, Xavier Paoletti, Francisco Bautista, et al.
Pageof 15